CAB39L Inhibitors is a chemical class encompassing compounds that are identified for their ability to influence the function of the protein CAB39L. This protein, involved in calcium signaling and related cellular processes, plays a role in various physiological pathways. The identification and study of inhibitors targeting CAB39L involve a multifaceted approach, integrating biochemical, pharmacological, and computational strategies to explore their interaction with the protein and its associated pathways. The primary method in identifying these inhibitors begins with a thorough understanding of CAB39L's role in cellular processes. Researchers study the protein's structure, function, and interaction with other cellular components, especially focusing on its involvement in calcium-dependent signaling pathways. This foundational knowledge guides the selection of chemical compounds that can interact with CAB39L or its associated pathways. Advanced techniques like high-throughput screening are employed to evaluate a wide range of compounds for their effects on CAB39L's activity. These screenings are designed to detect any alterations in the protein's function or its downstream effects in cellular processes. Compounds that exhibit an ability to alter CAB39L's activity are then studied further to understand their mode of action.
Following initial screenings, computational methods play a crucial role in refining the search for effective inhibitors. Computer-aided drug design utilizes the structural information of CAB39L to simulate and predict how various compounds might interact with the protein. This approach helps in identifying promising candidates for further experimental validation. Subsequent laboratory experiments involve detailed analysis of these compounds, assessing their direct interaction with CAB39L or their influence on the protein's role within cellular signaling pathways. These studies include a range of biochemical assays to elucidate the mechanisms by which these compounds alter CAB39L's activity. Additionally, the interactions of these inhibitors with other cellular components are scrutinized to ensure specificity and to understand their broader impact on cellular physiology. The development of CAB39L inhibitors is a dynamic field that integrates knowledge from molecular biology, chemistry, and computational sciences. This integrated approach ensures a comprehensive understanding of how these compounds interact with CAB39L, offering insights into their role in modulating the protein's function and related cellular activities. As such, CAB39L inhibitors represent a significant area of study, contributing to the broader understanding of protein functions and interactions in cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
2-APB, known to modulate IP3 receptors and store-operated calcium channels, could possibly inhibit CAB39L by altering intracellular calcium dynamics. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin, an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), could possibly inhibit CAB39L by disrupting calcium homeostasis, influencing calcium-mediated cellular processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM, a cell-permeable calcium chelator, could possibly inhibit CAB39L by sequestering intracellular calcium ions, affecting calcium-dependent signaling pathways. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, could possibly inhibit CAB39L by altering calcium ion influx, impacting calcium-dependent cellular signaling. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $153.00 $600.00 | 27 | |
Calmidazolium chloride, a calmodulin inhibitor, could possibly inhibit CAB39L by disrupting calmodulin-dependent calcium signaling, affecting pathways where CAB39L is active. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7, another calmodulin antagonist, could possibly inhibit CAB39L by altering calmodulin-mediated calcium signaling, affecting CAB39L-associated pathways. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $60.00 $301.00 | 2 | |
Nimodipine, a calcium channel blocker, could possibly inhibit CAB39L by modulating calcium ion flow, impacting calcium-dependent signaling processes. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $219.00 $765.00 | 19 | |
Ryanodine, which binds to and modulates ryanodine receptors, could possibly inhibit CAB39L by altering calcium release from intracellular stores, impacting calcium signaling pathways. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $73.00 $163.00 | 2 | |
Amlodipine, a calcium channel blocker, could possibly inhibit CAB39L by changing calcium ion dynamics, influencing CAB39L's role in calcium-mediated signaling. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $173.00 $612.00 | 3 | |
Cyclopiazonic Acid, an inhibitor of SERCA pumps, could possibly inhibit CAB39L by disrupting intracellular calcium levels, impacting calcium-dependent processes. | ||||||